{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:35:25Z","timestamp":1761647725818},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.jbspin.2010.01.008","type":"journal-article","created":{"date-parts":[[2010,2,20]],"date-time":"2010-02-20T04:47:31Z","timestamp":1266641251000},"page":"142-145","source":"Crossref","is-referenced-by-count":22,"title":["Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: Observational study of 30\u00a0cases in everyday practice"],"prefix":"10.1016","volume":"77","author":[{"given":"\u00c9ric","family":"Toussirot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9douard","family":"Pertuiset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Sordet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"Aug\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Wendling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Pallot-Prad\u00e8s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Collet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Charles","family":"Balblanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2010.01.008_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/187221307779815039","article-title":"Infectious complications with anti-TNF\u03b1 therapy in rheumatic diseases. A review","volume":"1","author":"Toussirot","year":"2007","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"10.1016\/j.jbspin.2010.01.008_bib2","article-title":"The risk of infections with biologic therapy for rheumatoid arthritis","author":"Furst","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.01.008_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.semarthrit.2008.01.001","article-title":"Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab","volume":"38","author":"Fleischmann","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.01.008_bib4","unstructured":"Summaries of product characteristics for Remicade\u00ae, Enbrel\u00ae and Humira\u00ae."},{"issue":"Suppl. 1","key":"10.1016\/j.jbspin.2010.01.008_bib5","first-page":"S1","article-title":"Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammation (CRI) section of the French Society of Rheumatology (Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie, SFR)","volume":"72","author":"Pham","year":"2005","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2010.01.008_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2010.01.008_bib7","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.01.008_bib8","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infections in rheumatoid arthritis","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.01.008_bib9","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependant increase in risk of hospitalization with infection among Swedish RA patients treated with TNF\u03b1 antagonists","volume":"66","author":"Askling","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2010.01.008_bib10","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.01.008_bib11","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2010.01.008_bib12","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment Results of a phase IIb randomized, double blind, placebo-controlled dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.01.008_bib13","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.01.008_bib14","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis. An open label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"Suppl.","key":"10.1016\/j.jbspin.2010.01.008_bib15","first-page":"S611","article-title":"Prospective follow-up of rituximab treatment in 965\u00a0patients with refractory rheumatoid arthritis (630\u00a0patients-year): tolerance and efficacy data from the French registry AIR (autoimmunity and rituximab)","volume":"58","author":"Gottenberg","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"Suppl.","key":"10.1016\/j.jbspin.2010.01.008_bib16","first-page":"S300","article-title":"Long-term safety of rituximab: 6-year follow-up of the rheumatoid arthritis (RA) clinical trials and re-treatment population","volume":"58","author":"Van Vollenhoven","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"Suppl.","key":"10.1016\/j.jbspin.2010.01.008_bib17","first-page":"S149","article-title":"Immunoglobulin levels and infection rates in patients with rheumatoid arthritis (RA) treated with repeated courses of rituximab","volume":"57","author":"Genovese","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.01.008_bib18","unstructured":"Summary of product characteristics for MabThera\u00ae."},{"issue":"Suppl.","key":"10.1016\/j.jbspin.2010.01.008_bib19","first-page":"S1","article-title":"Rituximab (Mabthera) therapy and safety management: clinical tool and guide","volume":"75","author":"Pham","year":"2008","journal-title":"Joint Bone Spine"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X10000096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X10000096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T23:20:40Z","timestamp":1544656840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X10000096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1297319X10000096"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2010.01.008","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}